Plexxikon Inc. reports positive clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients. PLX4032 targets the BRAFV600E mutation that occurs in about 50 percent of melanomas and about eight percent of solid tumors. Tumor shrinkage has been observed in nearly…

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and Naval Medical Research Center for the development of Dengue vaccines and point-of-care diagnostics. The goal of the R&D project is to evaluate the company’s Directed Expansion of Epitope Permutations…

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced final data results from a clinical trial evaluating IMO-2055, a monotherapy in patients with Renal Cell Carcinoma. Progression-free survival medians for treatment-naïve patients were 4.5 months at 0.16 mg/kg/week and 1.9 months at 0.64 mg/kg/week…

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an additional $2.3 million in funding for a $13.3 million contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) for the development of Radiation Countermeasure…

Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company's investigational prostate cancer product. Dendreon expects to prepare for commercialization of PROVENGE by the middle of next year. Dendreon further plans to…

Dr. J. Joseph Kim, CEO of Inovio Biomedical Corporation (NYSE Amex: INO), presented keynote remarks on universal DNA vaccines to prevent and treat infectious diseases (such as Influenza) at MIT’s Emerging Technologies Conference. Dr. Kim’s speech focused on the advantages of DNA vaccines versus…

XOMA Ltd. (Nasdaq:XOMA) is developing an antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including H1N1 and H5N1. XOMA will conduct the program under a $2.2 million subcontract with SRI International of…

Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President: Can you describe the top priorities or upcoming milestones for your company? Our phase 2 trial in chronic hepatitis C has completed enrollment and we expect to disclose end of treatment data at the annual meeting of the…

Dr. Steve Worland, Ph.D., Anadys Pharmaceuticals, Inc. President, CEO, & Director, discusses the latest developments at the company: Can you describe the top priorities or upcoming milestones for your company? Anadys is focused on the development of ANA598, our non-nucleoside polymerase…

Resolvyx Pharmaceuticals, Inc. announced the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) for RX-10045, a Resolvin therapeutic set to enter clinical trials. RX-10045 is a topical eye drop that treats chronic dry eye syndrome. Resolvins are naturally-occurring, small…